180 Life Sciences (NASDAQ: ATNF) today announced the publication of a review entitled “Dupuytren’s disease: a localized and accessible human fibrotic disorder” in the journal Trends in Molecular Medicine. In the article, the authors at the University of Oxford, led by Professor Jagdeep Nanchahal, chairman of the medical advisory board of 180 Life Sciences, describe the biology of Dupuytren’s disease, to which their important contributions are recognized by the International Dupuytren Award in 2019, 2020 and 2021. “This review provides an important update on our understanding of molecular basis of Dupuytren’s disease,” said Professor Marc Feldmann FRS, co-chairman of 180 Life Sciences. “By unravelling the signaling pathways and demonstrating their link to the genetics, Professor Nanchahal and his colleagues identified tumor necrosis factor (‘TNF’) as a therapeutic target in the laboratory and went on to demonstrate the efficacy of anti-TNF for the treatment of early-stage Dupuytren’s disease in a phase 2b clinical trial, the results which have been previously announced. Importantly, they have recently shown that anti-TNF treatment could also be cost-effective.”

To view the full press release, visit https://ibn.fm/zE5pu

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company driving groundbreaking studies into clinical programs, which are seeking to address major unmet medical needs. The company’s focus is a novel program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor).

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork